Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 2, Issue 1

February 19 2025

In Progress

In this Issue

Lymphoid Neoplasia
RESEARCH LETTER
CLINICAL TRIALS AND OBSERVATIONS

Lymphoid Neoplasia

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

David T. Yeung,Laura N. Eadie,Jacqueline Rehn,Susan L. Heatley,Barbara J. McClure,Elyse C. Page,Caitlin E. Schutz,Michael P. Osborn,Toby Trahair,Rosemary Sutton,Michelle J. Henderson,John Kwan,Sally Mapp,Luciano Dalla-Pozza,Kenneth Bradstock,Matthew Greenwood,Deborah L. White

View Articletitled, Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Supplemental data

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Matthew S. Davids,Jacob Ambrose,Enrico de Nigris,Jennifer Prescott,Siyang Leng,Mohammed Z. H. Farooqui,Shravanthi R. Gandra,Christina M. Zettler,Laura L. Fernandes,Ching Kun Wang,Mazyar Shadman

View Articletitled, Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Supplemental data

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Swaminathan P. Iyer,Shaker Dakhil,Michi M. Shinohara,Jasmine Zain,Mark Acosta,Francine Foss

View Articletitled, Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Jongseok Kang,Jason Ostergaard,Xiaohong Wang,Peter M. Gordon

View Articletitled, Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Supplemental data

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi,Ryota Chijimatsu,Yusuke Naoi,Yoshihiro Otani,Ryo Mizuta,Kentaro Fujii,Joji Ishida,Hiroyuki Murakami,Hideki Ujiie,Kazuhiro Ikeuchi,Tomohiro Urata,Keisuke Seike,Hideaki Fujiwara,Noboru Asada,Nobuharu Fujii,Ken-ichi Matsuoka,Yasuharu Sato,Yoshinobu Maeda,Daisuke Ennishi

View Articletitled, Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Supplemental data

RESEARCH LETTER

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor,Michael A. Golafshar,Katie L. Kunze,Edward D. Esplin,Robert L. Nussbaum,Erik Jessen,Brandie Heald,A. Keith Stewart,N. Jewel Samadder,P. Leif Bergsagel,Rafael Fonseca

View Articletitled, Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study
Clinical Trials & Observations

Yu Uemura,Masahide Yamamoto,Masataka Ishimura,Hirokazu Kanegane,Akihisa Sawada,Akihiro Hirakawa,Ken-Ichi Imadome,Mayumi Yoshimori,Masashi Nagata,Kouhei Yamamoto,Norio Shimizu,Ryuji Koike,Ayako Arai

View Articletitled, JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Supplemental data

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
Clinical Trials & Observations

Max J. Gordon,Sigrid Dubois,Milos D. Miljkovic,Samuel Ng,Bonita Bryant,Rahul Lakhotia,Christopher Melani,Stefania Pittaluga,Kevin Conlon,Thomas Waldmann,Louis M. Staudt,Wyndham H. Wilson,Mark Roschewski

View Articletitled, A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Clinical Trials & Observations

Naveen Pemmaraju,Tim C.P. Somervaille,Francesca Palandri,Claire Harrison,Rami S. Komrokji,Andrew Perkins,Rosa M. Ayala Diaz,David Lavie,Akihiro Tomita,Yang Feng,Qin Qin,Jason Harb,Akshanth R. Polepally,Jalaja Potluri,Jacqueline S. Garcia

View Articletitled, Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Supplemental data

All Issues

Advertisement intended for health care professionals

Lymphoid Neoplasia

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

RESEARCH LETTER

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

CLINICAL TRIALS AND OBSERVATIONS

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study
Clinical Trials & Observations

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
Clinical Trials & Observations

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Clinical Trials & Observations

ASH Publications

American Society of Hematology

Issue Archive

Lymphoid Neoplasia

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

RESEARCH LETTER

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

CLINICAL TRIALS AND OBSERVATIONS

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study Clinical Trials & Observations

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies Clinical Trials & Observations

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response Clinical Trials & Observations

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study
Clinical Trials & Observations

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies
Clinical Trials & Observations

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Clinical Trials & Observations